Does Wall Street Rate Sangamo Therapeutics Inc. (SGMO) Shares A Sell?

As of Friday close, Sangamo Therapeutics Inc.’s (NASDAQ:SGMO) stock was up $0.24, moving up 6.35 percent to $4.02. The average number of shares traded per day over the past five days has been 2,295,660 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.12 fall in that time frame. In the last twenty days, the average volume was 1,497,395, while in the previous 50 days, it was 1,312,012.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, SGMO stock retreated -27.57%. Shares of the company fell to $3.48 on 05/12/22, the lowest level in the past month. A 52-week high of $12.83 was reached on 01/04/22 after having rallying from a 52-week low of $3.48. Since the beginning of this year, SGMO’s stock price has dropped by -46.40% or -$3.48, and marked a new high 2 times. However, the stock has declined by -68.67% since its 52-week high.

Sangamo Therapeutics Inc. (SGMO) last reported insider trading activity 137 days ago on Dec 28. BIOGEN INC., the 10% Owner of the company, disposed of 2,764 shares for $8.51 on Dec 28. It resulted in a $23,522 divestment by the insider. BIOGEN INC. sold 600 shares at an average price of $8.56 on Dec 27. The insider now owns 24,155,230 shares following the transaction. On Dec 23, 10% Owner BIOGEN INC. sold 81,187 shares at $8.55 apiece. The transaction was valued at $694,530.

Valuation Metrics

The stock’s beta is 1.61. Besides these, the trailing price-to-sales (P/S) ratio of 5.53, the price-to-book (PB) ratio of 1.76.

Financial Health

In the three months ended September 29, Sangamo Therapeutics Inc.’s quick ratio stood at 2.90, while its current ratio was 2.90, showing that the company is able to pay off its debt. Based on annual data, SGMO earned $294.04 million in gross profit and brought in $110.7 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -48.90%. Return on equity (ROE) for the past 12 months was -45.20%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SGMO’s revenue rose 6.91% to $27.99 million during the quarter, while net income inched up to $28.23 million. While analysts expected Sangamo Therapeutics Inc. to report -$0.34 quarterly earnings, the actual figure was -$0.33 per share, beating the consensus estimate by 2.90%. During the quarter, the company generated -$34.59 million in EBITDA. The liabilities of Sangamo Therapeutics Inc. were 346.58 million at the end of its most recent quarter ended September 29, and its total debt was $48.08 million. The value of shareholders’ equity is $145.97 million.

Technical Picture

This quick technical analysis looks at Sangamo Therapeutics Inc.’s (SGMO) price momentum. With a historical volatility rate of 97.09%, the RSI 9-day stood at 42.15% on 13 May.

With respect to its five-day moving average, the current Sangamo Therapeutics Inc. price is down by -2.90% percent or -$0.12. At present, SGMO shares trade -23.57% below its 20-day simple moving average and -51.27% percent below its 100-day simple moving average. However, the stock is currently trading approximately -28.47% below its SMA50 and -58.64% below its SMA200.

Stochastic coefficient K was 22.22% and Stochastic coefficient D was 14.58%, while ATR was 0.37. Given the Stochastic reading of 40.91% for the 14-day period, the RSI (14) reading has been calculated as 39.66%. As of today, the MACD Oscillator reading stands at -0.26, while the 14-day reading stands at -0.37.

Analyst Ratings

RBC Capital Mkts launched its rating on Sangamo Therapeutics Inc. (NASDAQ: SGMO) to an Outperform in a note to investors on May 04, 2021. Sangamo Therapeutics Inc. (SGMO) has been rated Overweight by analysts. According to 0 brokerage firms , SGMO is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Sangamo Therapeutics Inc. stock as buy, with 7 recommending it as overweight.

With a median target price of $17.00, the current consensus forecast for the stock is $4.40 – $25.00. Based on these forecasts, analysts predict Sangamo Therapeutics Inc. (SGMO) will achieve an average price target of $16.04.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles